Metabolic Network Prediction of Drug Side Effects

Cell Systems

Volumn 2, Issue 3, 2016, Pages 209-213

  Shaked, Itay ^a   Oberhardt, Matthew A ^a,b   Atias, Nir ^a   Sharan, Roded ^a   Ruppin, Eytan ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b Institute of Advanced Computer Science   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADVERSE DRUG REACTION; ARRAY OF MODEL BASED PHENOTYPE PREDICTOR; ARTICLE; EXTRAPYRAMIDAL SYNDROME; HUMAN; HUMAN GENOME SCALE METABOLIC MODEL; INTERSTITIAL NEPHRITIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SUPPORT VECTOR MACHINE; AREA UNDER THE CURVE; DRUG INTERACTION; DRUG REPOSITIONING; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; METABOLIC ENGINEERING; METABOLISM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AREA UNDER CURVE; BIOMARKERS; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG REPOSITIONING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; METABOLIC ENGINEERING; METABOLIC NETWORKS AND PATHWAYS;

EID: 84962140627     PISSN: 24054712     EISSN: 24054720     Source Type: Journal    
DOI: 10.1016/j.cels.2016.03.001     Document Type: Article

References (28)

1. N. Atias, and R. Sharan An algorithmic framework for predicting side effects of drugs J. Comput. Biol. 18 2011 207 218
2. A. Bordbar, and B.O. Palsson Using the reconstructed genome-scale human metabolic network to study physiology and pathology J. Intern. Med. 271 2012 131 141
3. L. Breiman Random forests Mach. Learn. 45 2001 5 32
4. F. Cheng, W. Li, X. Wang, Y. Zhou, Z. Wu, J. Shen, and Y. Tang Adverse drug events: database construction and in silico prediction J. Chem. Inf. Model. 53 2013 744 752
5. N.C. Duarte, S.A. Becker, N. Jamshidi, I. Thiele, M.L. Mo, T.D. Vo, R. Srivas, and B.O. Palsson Global reconstruction of the human metabolic network based on genomic and bibliomic data Proc. Natl. Acad. Sci. USA 104 2007 1777 1782
6. M. Duran-Frigola, and P. Aloy Analysis of chemical and biological features yields mechanistic insights into drug side effects Chem. Biol. 20 2013 594 603
7. O. Folger, L. Jerby, C. Frezza, E. Gottlieb, E. Ruppin, and T. Shlomi Predicting selective drug targets in cancer through metabolic networks Mol. Syst. Biol. 7 2011 501
8. M. Hay, D.W. Thomas, J.L. Craighead, C. Economides, and J. Rosenthal Clinical development success rates for investigational drugs Nat. Biotechnol. 32 2014 40 51
9. L. Jerby, T. Shlomi, and E. Ruppin Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism Mol. Syst. Biol. 6 2010 401
10. T. Juan-Blanco, M. Duran-Frigola, and P. Aloy IntSide: a web server for the chemical and biological examination of drug side effects Bioinformatics 31 2015 612 613
11. C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, A. Frolkis, A. Pon, K. Banco, C. Mak, V. Neveu, and et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 39 2011 D1035 D1041
12. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
13. M. Kuhn, M. Campillos, I. Letunic, L.J. Jensen, and P. Bork A side effect resource to capture phenotypic effects of drugs Mol. Syst. Biol. 6 2010 343
14. J. Lazarou, B.H. Pomeranz, and P.N. Corey Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1998 1200 1205
15. N.E. Lewis, G. Schramm, A. Bordbar, J. Schellenberger, M.P. Andersen, J.K. Cheng, N. Patel, A. Yee, R.A. Lewis, R. Eils, and et al. Large-scale in silico modeling of metabolic interactions between cell types in the human brain Nat. Biotechnol. 28 2010 1279 1285
16. R. Mahadevan, and C.H. Schilling The effects of alternate optimal solutions in constraint-based genome-scale metabolic models Metab. Eng. 5 2003 264 276
17. A. Mardinoglu, and J. Nielsen Systems medicine and metabolic modelling J. Intern. Med. 271 2012 142 154
18. A. Mardinoglu, R. Agren, C. Kampf, A. Asplund, I. Nookaew, P. Jacobson, A.J. Walley, P. Froguel, L.M. Carlsson, M. Uhlen, and J. Nielsen Integration of clinical data with a genome-scale metabolic model of the human adipocyte Mol. Syst. Biol. 9 2013 649
19. M.A. Oberhardt, B.O. Palsson, and J.A. Papin Applications of genome-scale metabolic reconstructions Mol. Syst. Biol. 5 2009 320
20. E. Pauwels, V. Stoven, and Y. Yamanishi Predicting drug side-effect profiles: a chemical fragment-based approach BMC Bioinformatics 12 2011 169
21. M. Pirmohamed, S. James, S. Meakin, C. Green, A.K. Scott, T.J. Walley, K. Farrar, B.K. Park, and A.M. Breckenridge Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients BMJ 329 2004 15 19
22. T. Shlomi, M.N. Cabili, M.J. Herrgård, B.O. Palsson, and E. Ruppin Network-based prediction of human tissue-specific metabolism Nat. Biotechnol. 26 2008 1003 1010
23. T. Shlomi, M.N. Cabili, and E. Ruppin Predicting metabolic biomarkers of human inborn errors of metabolism Mol. Syst. Biol. 5 2009 263
24. I. Thiele, N. Swainston, R.M. Fleming, A. Hoppe, S. Sahoo, M.K. Aurich, H. Haraldsdottir, M.L. Mo, O. Rolfsson, M.D. Stobbe, and et al. A community-driven global reconstruction of human metabolism Nat. Biotechnol. 31 2013 419 425
25. Y. Yamanishi, E. Pauwels, and M. Kotera Drug side-effect prediction based on the integration of chemical and biological spaces J. Chem. Inf. Model. 52 2012 3284 3292
26. K. Yizhak, S.E. Le Dévédec, V.M. Rogkoti, F. Baenke, V.C. de Boer, C. Frezza, A. Schulze, B. van de Water, and E. Ruppin A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration Mol. Syst. Biol. 10 2014 744
27. A. Zelezniak, T.H. Pers, S. Soares, M.E. Patti, and K.R. Patil Metabolic network topology reveals transcriptional regulatory signatures of type 2 diabetes PLoS Comput. Biol. 6 2010 e1000729
28. D.C. Zielinski, F.V. Filipp, A. Bordbar, K. Jensen, J.W. Smith, M.J. Herrgard, M.L. Mo, and B.O. Palsson Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis Nat. Commun. 6 2015 7101